Montel, Rachel A. http://orcid.org/0000-0001-6177-6839
Munoz-Zuluaga, Carlos
Stiles, Katie M.
Crystal, Ronald G.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R41AA027739)
Article History
Received: 21 July 2021
Revised: 24 September 2021
Accepted: 8 October 2021
First Online: 19 November 2021
Competing interests
: RGC is a consultant and holds equity in LEXEO Therapeutics; LEXEO has an option with Weill Cornell Medical College to license the ALDH2 gene therapy program. RGC is also a co-inventor on a patent application related to this topic (US application number 16/321,023).